Zucara Therapeutics announced highly positive results from its proof-of-concept Phase 1b trial of ZT-01 in people with Type 1 diabetes (“T1D”). Please see the press release here. Why this news is important:
- This trial confirms ZT-01’s mechanism of action in restoring glucagon release in patients with T1D.
- First-in-class ZT-01, meaningfully restored glucagon release in nearly 90% of treated patients compared to placebo (p<0.0001). This therapy has the potential to become the first therapeutic to prevent hypoglycemia in people with insulin-dependent diabetes.
- Positive results from this trial will enable Zucara to further evaluate ZT-01 in a multi-center Phase 2 trial in the U.S. and Canada; the Company plans to file the required regulatory applications by the end of this year
Zucara was founded funded by TIAP based on innovation from the University of Toronto and remains a TIAP portfolio company.